IMNN
Imunon, Inc.
There isn't enough reported data to score IMNN yet.
LLY
Eli Lilly and Company
LLY's fundamentals are strong: revenue grew 46% and it turned 23% of its revenue into free cash flow. At 46x earnings, it's trading in line with its usual 48x. Analysts expect that strong growth to continue.
IMNN Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Weak | |
| Unavailable | |
| Unavailable |
IMNN's revenue is currently stable, but its profitability is weak. There isn't enough data to rate its cash flow and balance sheet.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
IMNN PE Valuation
IMNN has no meaningful PE right now: it lost money over the past year.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
IMNN Forward outlook
There aren't enough analyst estimates for IMNN to show an outlook.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
IMNN Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$5.26 | +$6.00 |
| Q2 2026 | -$5.78 | +$9.42 |
| Q1 2026 | -$7.39 | +$13.31 |
| Q4 2025 | -$10.75 | +$13.55 |
| Q3 2025 | -$11.26 | +$16.79 |
| Q2 2025 | -$15.20 | +$13.30 |
| Q1 2025 | -$20.70 | +$9.30 |
| Q4 2024 | -$24.30 | +$8.10 |
IMNN is still losing money, but far less than before: $5.26 per share over the past year, against $191.25 at its worst in early 2020.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over IMNN on earnings quality, reporting a profit while its opponent remains loss making.
IMNN Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q4 2022 | $125K | 0% |
| Q3 2022 | $125K | 0% |
| Q2 2022 | $125K | 0% |
| Q1 2022 | $125K | 0% |
| Q4 2021 | $125K | 0% |
| Q3 2021 | $125K | 0% |
| Q2 2021 | $125K | 0% |
| Q1 2021 | $125K | 0% |
LLY has the stronger quarterly revenue trend. Revenue is flat for IMNN versus up 39% for LLY.
| Quarter | Margin | YoY |
|---|---|---|
| Q4 2022 | -5541% | -1149 points |
| Q3 2022 | -4940% | -890 points |
| Q2 2022 | -4783% | -726 points |
| Q1 2022 | -4674% | -367 points |
| Q4 2021 | -4393% | -558 points |
| Q3 2021 | -4049% | -722 points |
| Q2 2021 | -4057% | -244 points |
| Q1 2021 | -4307% | -494 points |
IMNN's operating margin was −5541% last quarter, down 1149 points from the same quarter a year ago, near the bottom of its range since 2019.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY's revenue has grown year over year for 14 quarters in a row: $24.4B last quarter, up 39% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY's operating margin was 34% last quarter, down 6.6 points from the same quarter a year ago.
IMNN Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$3.2M | +$1.2M |
| Q4 2025 | -$3.7M | +$775.2K |
| Q3 2025 | -$4.4M | -$382.7K |
| Q2 2025 | -$3M | +$1.5M |
| Q1 2025 | -$3.1M | +$2.8M |
| Q4 2024 | -$4.4M | -$663.6K |
| Q3 2024 | -$4.1M | +$654.4K |
| Q2 2024 | -$4.5M | +$2.3M |
LLY has the stronger cash trend. Its trailing FCF is up 259% versus its history, compared with IMNN at up 22%.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY generated $19.7B in free cash flow over the past year, up 112% from the year before.
IMNN Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +14% | +715K shares |
| 1 year | +366% | +4.7M shares |
| 3 years | +977% | +5.4M shares |
| 5 years | +3823% | +5.8M shares |
IMNN has 6M diluted shares, up 366% from a year ago.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over IMNN on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
IMNN Net Leverage
IMNN's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
IMNN Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 25.1 | Oversold |
| Stochastic | 8.5 | Oversold |
IMNN's weekly RSI is 25 (oversold) and its Stochastic is 9 (oversold).
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
IMNN PE vs Healthcare Sector
IMNN has no meaningful PE right now: it lost money over the past year.
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
IMNN Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.05 | 39% below |
| 20 week MA | $1.41 | 55% below |
| 50 week MA | $2.36 | 73% below |
| 100 week MA | $6.65 | 90% below |
| 200 week MA | $11.7 | 95% below |
IMNN is in a downtrend: it's below all five of its weekly moving averages, and 95% below its 200-week average.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over IMNN on trend strength, trading above more of its moving averages.
IMNN Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $366.8 | $166.5 | -55% |
| 2021 | $166.5 | $139.5 | -16% |
| 2022 | $139.5 | $20.0 | -86% |
| 2023 | $20.0 | $10.2 | -49% |
| 2024 | $10.2 | $11.9 | +17% |
| 2025 | $11.9 | $3.15 | -74% |
| 2026 YTD | $3.15 | $0.64 | -80% |
IMNN has finished lower in five of the last six years. It's down 80% so far in 2026.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over IMNN on returns for 2026, with the stronger performance.